Can I take trazodone and Dayvigo (lemborexant) together, and what precautions should I follow?

Combining Trazodone and Dayvigo: Not Recommended

You should not combine trazodone with Dayvigo (lemborexant) for insomnia treatment. Instead, discontinue trazodone and use Dayvigo alone, as trazodone lacks efficacy evidence while Dayvigo is FDA-approved with proven benefits for both sleep onset and maintenance.

Why This Recommendation

Trazodone Should Not Be Used for Insomnia

The 2020 VA/DoD guidelines explicitly advise against using trazodone for chronic insomnia disorder 1. The evidence is clear:

• No improvement in objective sleep measures: Systematic reviews found no differences in sleep efficiency or discontinuation rates between trazodone (50-150 mg) and placebo 1
• Minimal subjective benefit: While trazodone improved subjective sleep quality, it showed no differences in sleep onset latency, total sleep time, or wake after sleep onset 1
• Poor evidence quality: Studies had very short durations (mean 1.7 weeks) with only 1-4 weeks follow-up 1
• Adverse effects outweigh benefits: The low-quality efficacy evidence was deemed insufficient compared to its adverse effect profile 1

The 2017 American Academy of Sleep Medicine guidelines similarly recommend against trazodone for sleep onset or maintenance insomnia 2.

Dayvigo Is Effective and FDA-Approved

Dayvigo (lemborexant) is FDA-approved specifically for insomnia characterized by difficulties with sleep onset and/or sleep maintenance 3. The evidence demonstrates:

• Rapid and sustained efficacy: Improvements in both objective and subjective sleep measures occur within 1-2 nights and persist for 6-12 months 4, 5, 6
• Superior objective outcomes: Lemborexant ranked highest among insomnia treatments for 3 out of 4 polysomnography-measured outcomes (total sleep time, latency to persistent sleep, and sleep efficiency) 7
• Dose-dependent benefits: Both 5 mg and 10 mg doses significantly reduce sleep onset latency, wake after sleep onset, and improve sleep efficiency compared to placebo 4, 5

Risks of Combining CNS Depressants

The FDA label explicitly warns that co-administration with other CNS depressants increases the risk of CNS depression and daytime impairment 3. Specifically:

• Combining Dayvigo with other CNS depressants (including tricyclic antidepressants like trazodone) causes additive effects 3
• Dosage adjustments of both drugs may be necessary when administered together 3
• Using Dayvigo with other insomnia drugs is not recommended 3
• Increased risk of next-day somnolence, falls (particularly in elderly), and impaired driving ability 3

Clinical Algorithm

Step 1: Assess Current Regimen

• If patient is on trazodone for insomnia → Plan to discontinue

Step 2: Initiate Dayvigo Monotherapy

• Start Dayvigo 5 mg once nightly, immediately before bed with ≥7 hours remaining for sleep 3
• Take on empty stomach (time to sleep onset delayed if taken with/after meals) 3
• May increase to 10 mg based on clinical response and tolerability 3

Step 3: Taper Trazodone

• Gradually discontinue trazodone over 1-2 weeks while starting Dayvigo
• Monitor for any withdrawal symptoms or rebound insomnia

Step 4: Monitor Response

• Assess sleep onset, sleep maintenance, and daytime functioning within first week
• Evaluate for adverse effects (somnolence most common at 7-10%) 3

Important Precautions

Drug Interactions to Avoid

• Avoid moderate/strong CYP3A inhibitors (fluconazole, itraconazole, clarithromycin) - these increase lemborexant levels 1.6-4 fold 3, 8
• Avoid moderate/strong CYP3A inducers (rifampin, carbamazepine, St. John's wort) - these decrease lemborexant by >90% 3, 8
• Maximum 5 mg dose with weak CYP3A inhibitors (ranitidine, chlorzoxazone) 3
• Avoid alcohol - increases lemborexant levels and worsens postural stability/memory 3

Special Populations

• Moderate hepatic impairment: Maximum 5 mg dose 3
• Severe hepatic impairment: Not recommended 3
• Elderly patients: Higher risk of falls due to drowsiness 3

Common Adverse Effects

• Somnolence/fatigue (7-10% vs 1% placebo) 3
• Headache (5-6% vs 3% placebo) 3
• Nightmares (2% vs 0% placebo) 3
• Sleep paralysis (1.3-1.6% vs 0% placebo) 3

Bottom Line

Discontinue trazodone and use Dayvigo alone. Trazodone lacks evidence for insomnia efficacy and combining it with Dayvigo creates unnecessary CNS depression risk without added benefit. Dayvigo monotherapy at 5-10 mg provides proven, sustained improvements in both sleep onset and maintenance with an acceptable safety profile 4, 5, 6.